Phaseline

Companies › Yong Zhao, MD, PhD

Yong Zhao, MD, PhD: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Stem Cell Educator therapy
Autologous immune cell education using cord blood-derived stem cells to induce immune tole
–Phase 3Type 1 DiabetesOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04011020Stem Cell Educator therapyPhase 3Type 1 DiabetesMetabolic and endocrineOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Spur Therapeutics iECURE Grace Science BioLab Holdings AB Biotics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.